The Role of Ischemia-modified Albumin as a Biomarker in Preeclampsia

Abstract

Objective Ischemia-modified albumin (IMA)is a modified type of albumin protein that is formed under oxidative stress. This study aims to compare the levels of serum IMA between normotensive and preeclamptic pregnancies and to evaluate the relationship between the severity of the disease.

Methods A total of 90 pregnant women aged between 18 and 45 years participated in this cross-sectional study. The levels of serum IMA were measured by enzyme-linked immunosorbent assay in 30 preeclamptic pregnant women with the severe signs of the disease, 30 preeclamptic pregnant women, and 30 normotensive pregnant women.. The study was designed as a cross-sectional clinical study.

Results When the demographic characteristics were examined, statistically significant differences were found between the groups in terms of age, gestational week at birth and blood pressure. Age was higher in the preeclampsia with signs of severity group than in the normotensive group (p = 0.033). Pregnancy week was significantly the lowest in the preeclampsia with the severity signs group (p = 0.004). In normotensive patients, IMA levels were lower than in the preeclampsia groups (p < 0.001) but there was no significant difference in terms of severity of disease (p = 0.191). According to laboratory data; only the creatinine level was significantly different between the groups.

Conclusion The levels of serum IMA were higher in patients with preeclampsia than in healthy pregnancies. However, there was no significant correlation in terms of preeclampsia severity; more extensive, prospective and long-term studies are needed.

Keywords

preeclampsia - ischemia modified albumin - hypertension - pregnancy

Contributors

All authors participated in the concept and design of the present study; analysis and interpretation of data; drafting or revising of the manuscript, and they have approved the manuscript as submitted. All authors are responsible for the reported research.

• References

• 1 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376 (9741): 631-644 . Doi: 10.1016/S0140-6736(10)60279-6
• 2 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131 . Doi: 10.1097/01.AOG.0000437382.03963.88
• 3 Ustün Y, Engin-Ustün Y, Oztürk O, Alanbay I, Yaman H. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. J Matern Fetal Neonatal Med 2011; 24 (03) 418-421 . Doi: 10.3109/14767058.2010.497879
• 4 Anwaruddin S, Januzzi Jr JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005; 123 (01) 140-145 . Doi: 10.1309/4bctg5ucymqfwblr
• 5 Guven S, Alver A, Mentese A, Ilhan FC, Calapoglu M, Unsal MA. The novel ischemia marker ‘ischemia-modified albumin’ is increased in normal pregnancies. Acta Obstet Gynecol Scand 2009; 88 (04) 479-482 . Doi: 10.1080/00016340902777517
• 6 van Rijn BB, Franx A, Sikkema JM, van Rijn HJ, Bruinse HW, Voorbij HA. Ischemia modified albumin in normal pregnancy and preeclampsia. Hypertens Pregnancy 2008; 27 (02) 159-167 . Doi: 10.1080/10641950701885147
• 7 Knöfler M. Critical growth factors and signalling pathways controlling human trophoblast invasion. Int J Dev Biol 2010; 54 (2-3): 269-280 . Doi: 10.1387/ijdb.082769mk
• 8 Bahinipati J, Mohapatra PC. Ischemia modified albumin as a marker of oxidative stress in normal pregnancy. J Clin Diagn Res 2016; 10 (09) BC15-BC17 . Doi: 10.7860/JCDR/2016/21609.8454
• 9 Laganà AS, Favilli A, Triolo O, Granese R, Gerli S. Early serum markers of pre-eclampsia: are we stepping forward?. J Matern Fetal Neonatal Med 2016; 29 (18) 3019-3023 . Doi: 10.3109/14767058.2015.1113522
• 10 Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010; (09) CD008148 . Doi: 10.1002/14651858.CD008148.pub2
• 11 Rossi A, Bortolotti N, Vescovo S, Romanello I, Forzano L, Londero AP. , et al. Ischemia-modified albumin in pregnancy. Eur J Obstet Gynecol Reprod Biol 2013; 170 (02) 348-351 . Doi: 10.1016/j.ejogrb.2013.06.037
• 12 Iacovidou N, Briana DD, Boutsikou M, Liosi S, Baka S, Boutsikou T. , et al. Cord blood ischemia-modified albumin levels in normal and intrauterine growth restricted pregnancies. Mediators Inflamm 2008; 2008: 523081 . Doi: 10.1155/2008/523081
• 13 Papageorghiou AT, Prefumo F, Leslie K, Gaze DC, Collinson PO, Thilaganathan B. Defective endovascular trophoblast invasion in the first trimester is associated with increased maternal serum ischemia-modified albumin. Hum Reprod 2008; 23 (04) 803-806 . Doi: 10.1093/humrep/den029
• 14 Vyakaranam S, Bhongir AV, Patlolla D, Chintapally R. Maternal serum ischemia modified albumin as a marker for hypertensive disorders of pregnancy: a pilot study. Int J Reprod Contracept Obstet Gynecol 2015; 4 (03) 611-616 . Doi: 10.18203/2320-1770.ijrcog20150061
• 15 Gafsou B, Lefèvre G, Hennache B, Houfflin Debarge V, Ducloy-Bouthors AS. Maternal serum ischemia-modified albumin: a biomarker to distinguish between normal pregnancy and preeclampsia?. Hypertens Pregnancy 2010; 29 (01) 101-111 . Doi: 10.3109/10641950902968601
• 16 Delić R, Štefanović M, Krivec Š, Weber V. Statistical regression model of standard and new laboratory markers and its usefulness in prediction of preeclampsia. J Matern Fetal Neonatal Med 2014; 27 (04) 388-392 . Doi: 10.3109/14767058.2013.818121
• 17 Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49 (02) 177-184 . Doi: 10.1515/CCLM.2011.037
• 18 Oran I, Oran B. Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of “N-Terminal Modification” to “Fatty Acid Occupation” of albumin. Dis Markers 2017; 2017: 5692583 . Doi: 10.1155/2017/5692583